<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04699266</url>
  </required_header>
  <id_info>
    <org_study_id>PHY2002</org_study_id>
    <nct_id>NCT04699266</nct_id>
  </id_info>
  <brief_title>Clinical Investigation of the Multifocal IOL POD F GF in Cataracteous Eyes</brief_title>
  <official_title>Clinical Investigation of the Multifocal Intraocular Lens (IOL) POD F GF in Cataracteous Eyes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beaver-Visitec International, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beaver-Visitec International, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate effectiveness and safety of the POD F GF Intraocular Lens (IOL) when implanted to&#xD;
      replace the natural lens following cataract removal&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Since the investigational lens, like conventional IOLs, is a posterior chamber lens which is&#xD;
      widely implanted following cataract extraction, phacoemulsification is adopted. To assess the&#xD;
      binocular vision, the investigational lens will be bilaterally implanted. Considering the&#xD;
      safety of the study subjects, the time of implant to the remaining eye (2nd eye) will be&#xD;
      decided based on the results of the 1st implant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Binocular Best corrected distance visual acuity (5 m)</measure>
    <time_frame>Postoperative Day 120-180 (4-6 months)</time_frame>
    <description>CDVA measured with ETDRS charts placed in 5m distance with best aided corrective glasses according to ISO 11979-7:2014.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Binocular Distance corrected near visual acuity (40 cm)</measure>
    <time_frame>Postoperative Day 120-180 (4-6 months)</time_frame>
    <description>DCIVA measured with ETDRS charts placed in 40cm distance with corrective glasses for far distance according to ISO 11979-7:2014.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Binocular Distance corrected intermediate visual acuity (80 cm)</measure>
    <time_frame>Postoperative Day 120-180 (4-6 months)</time_frame>
    <description>DCIVA measured with ETDRS charts placed in 80cm distance with corrective glasses for far distance according to ISO 11979-7:2014.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Binocular photopic best corrected distance visual acuity (5 m)</measure>
    <time_frame>Postoperative Day 120-180</time_frame>
    <description>DCIVA outcomes at 5m distance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocular and binocular photopic uncorrected distance visual acuity (5 m)</measure>
    <time_frame>Postoperative Day 120-180</time_frame>
    <description>UDVA outcomes at n 5m distance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocular and binocular photopic uncorrected intermediate visual acuity and binocular distance corrected intermediate visual acuity (80 cm)</measure>
    <time_frame>Postoperative Day 120-180</time_frame>
    <description>DCIVA outcomes at 80cm distance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocular and binocular photopic uncorrected near visual acuity and binocular distance corrected visual acuity (40cm)</measure>
    <time_frame>Postoperative Day 120-180</time_frame>
    <description>DCNVA outcomes at 40cm distance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binocular photopic defocus curves</measure>
    <time_frame>Postoperative Day 120-180</time_frame>
    <description>To assess the visual acuity for different distances, defocus curves under photopic light conditions are measured. This test is performed with best distance corrected refraction and spherical additions ranging from -5.0 D to +1.5 D.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast Sensitivity under photopic light conditions</measure>
    <time_frame>Postoperative Day 120-180</time_frame>
    <description>Contrast Sensitivity outcomes under photopic light conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast Sensitivity under mesopic light conditions</measure>
    <time_frame>Postoperative Day 120-180</time_frame>
    <description>Contrast Sensitivity outcomes under photopic light conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Vison: VFQ-11 Questionnaire</measure>
    <time_frame>Postoperative Day 120-180</time_frame>
    <description>Outcomes measures of a questionnaire to address the general patient satisfaction and possible side effects of the treatment. For this study, the validated and verified Visual Functioning Questionnaire - 25 (VFQ-25) will be used. The maximum score for each questionaire is 100.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Cataract</condition>
  <condition>Lens Opacities</condition>
  <condition>Presbyopia</condition>
  <arm_group>
    <arm_group_label>Experimental: POD F GF IOL Implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: POD F GF IOL Implantation experimental Multi-center, single-arm, non-masked study Mono- or bilateral implantation of trifocal intraocular lenses POD F GF</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Assigned Intervention (POD F GF)</intervention_name>
    <description>The investigational lens (POD F GF )will be implanted to both eyes in subjects with bilateral cataract. Registration of patients and the implantation of the investigational lens (POD F GF) will be conducted in consideration of securing 44 eyes in 22 subjects as the analysis subjects</description>
    <arm_group_label>Experimental: POD F GF IOL Implantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults, 20 years of age or older at the time of informed consent, of either gender,&#xD;
             diagnosed with bilateral cataracts;&#xD;
&#xD;
          2. Able to comprehend and sign a statement of informed consent;&#xD;
&#xD;
          3. Willing and able to complete all required postoperative visits;&#xD;
&#xD;
          4. Calculated lens power within the available range;&#xD;
&#xD;
          5. Planned cataract removal by phacoemulsification;&#xD;
&#xD;
          6. Potential postoperative BCDVA of 0.5 decimal or better in both eyes;&#xD;
&#xD;
          7. Subject with preoperative astigmatism &lt; 1.0 D&#xD;
&#xD;
          8. Clear intraocular media other than cataract in both eyes;&#xD;
&#xD;
          9. The subject must be able to undergo second eye surgery within 30 days of the first eye&#xD;
             surgery.&#xD;
&#xD;
        [Justification for the inclusion criteria]&#xD;
&#xD;
          1. and 5: Cataract extraction is the indication of the clinical study.&#xD;
&#xD;
          2. and 3: One of GCP requirements 4: Essential condition for implant of the&#xD;
             investigational lens. 6, 7, 8 and 9: Conditions to minimize the potential non-IOL&#xD;
             factors which may affect the visual acuity data&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        [Exclusion Criteria Prior to Surgery] The patient who meets any criteria specified in the&#xD;
        following 1) through 22).&#xD;
&#xD;
          1. Irregular corneal aberration that affects postoperative visual function as&#xD;
             demonstrated by corneal topography;&#xD;
&#xD;
          2. Inflammation or edema (swelling) of the cornea affecting post-operative visual acuity;&#xD;
&#xD;
          3. Subjects with diagnosed degenerative visual disorders (e.g. macular degeneration or&#xD;
             other retinal disorders) that are predicted to cause future acuity losses to a level&#xD;
             worse than 0.5 decimal for BCDVA;&#xD;
&#xD;
          4. Subjects who may be expected to require ocular surgery (other than blepharo-surgery,&#xD;
             laser surgery of fundus and YAG capsulotomy) during the study;&#xD;
&#xD;
          5. Previous refractive surgery;&#xD;
&#xD;
          6. Amblyopia;&#xD;
&#xD;
          7. Clinically severe corneal dystrophy (eg., epithelial, stromal, or endothelial&#xD;
             dystrophy), keratitis, keratoconjunctivitis, keratouveitis, keratopathy, or&#xD;
             kerectasia;&#xD;
&#xD;
          8. Diabetic retinopathy;&#xD;
&#xD;
          9. Extremely shallow anterior chamber, not due to swollen cataract;&#xD;
&#xD;
         10. Microphthalmos;&#xD;
&#xD;
         11. Current or previous retinal detachment;&#xD;
&#xD;
         12. Previous corneal transplant;&#xD;
&#xD;
         13. Recurrent severe anterior or posterior segment inflammation of unknown etiology;&#xD;
&#xD;
         14. Rubella or traumatic cataract;&#xD;
&#xD;
         15. Iris neovascularization;&#xD;
&#xD;
         16. Glaucoma or ocular hypertension;&#xD;
&#xD;
         17. Aniridia;&#xD;
&#xD;
         18. Optic nerve atrophy;&#xD;
&#xD;
         19. Planned clear lensectomy (no lens opacity)&#xD;
&#xD;
         20. Pregnancy, lactating or possible pregnant;&#xD;
&#xD;
         21. Participation in any clinical study (drug or device) within 3 months prior to&#xD;
             participating this study, planned participation another clinical study during this&#xD;
             study, or currently participating in another study.&#xD;
&#xD;
         22. Disqualified by the investigator or the sub-investigator because of physical or&#xD;
             ophthalmic diseases.&#xD;
&#xD;
        [Exclusion Criteria During Surgery] The patient who meets any criteria specified in the&#xD;
        following 1) through 7).&#xD;
&#xD;
          1. Mechanical or surgical manipulation required to enlarge the pupil;&#xD;
&#xD;
          2. Excessive iris mobility;&#xD;
&#xD;
          3. Significant vitreous loss;&#xD;
&#xD;
          4. Significant anterior chamber hyphema;&#xD;
&#xD;
          5. Uncontrollable intraocular pressure;&#xD;
&#xD;
          6. Zonular or capsular rupture or tear;&#xD;
&#xD;
          7. IOL could not be fixed in the lens capsule;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kazunori Miyata, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Miyata Eye Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rebecca McQuaid, PhD</last_name>
    <phone>+353871212615</phone>
    <email>Rmcquaid@bvimedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Senta Tsunemitsu</last_name>
    <phone>+353871212615</phone>
    <email>tsenta@bvimedical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Miyata Eye Hospital</name>
      <address>
        <city>Miyata</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miyata Kazunori, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 16, 2020</study_first_submitted>
  <study_first_submitted_qc>January 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2021</study_first_posted>
  <last_update_submitted>April 30, 2021</last_update_submitted>
  <last_update_submitted_qc>April 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intraocular lens</keyword>
  <keyword>Trifocal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Presbyopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

